Urocanic acid - Herantis Pharma

Drug Profile

Urocanic acid - Herantis Pharma

Alternative Names: Ci-UCA Emulsion Cream; Cis-UCA; Cis-UCA Eye Drops; ProtoCure; UCA-001; UCA-002

Latest Information Update: 13 Oct 2015

Price : $50

At a glance

  • Originator BioCis Pharma
  • Developer Herantis Pharma
  • Class Acrylates; Antineoplastics; Imidazoles; Immunotherapies; Skin disorder therapies; Small molecules
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Atopic dermatitis; Dry eyes

Highest Development Phases

  • Phase II Dry eyes
  • Suspended Atopic dermatitis
  • No development reported Bladder cancer; Interstitial cystitis
  • Discontinued Plaque psoriasis

Most Recent Events

  • 12 Oct 2015 Urocanic acid - Herantis Pharma is available for licensing-http://herantis.com/wp-content/uploads/2015/09/Herantis_NLS_2015.pdf
  • 11 Mar 2015 Herantis Pharma completes enrolment in its phase II trial for Dry eyes in USA (Ophthalmic) (9175902; NCT02326090)
  • 01 Dec 2014 Phase-II clinical trials in Dry eyes in USA (Ophthalmic) (NCT02326090)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top